GLP-1 comparison guide

Semaglutide vs tirzepatide: how to compare online weight-loss options

Compare semaglutide and tirzepatide by mechanism, expected weight-loss range, side-effect profile, FDA-approved brand options, compounded access, cost, eligibility, and clinician-review questions.

Safe comparison path

1

Name the exact product first: compounded semaglutide, Wegovy, Ozempic, compounded tirzepatide, Zepbound, or Mounjaro.

2

Match the label and goal: weight management, type 2 diabetes, cardiovascular-risk reduction, sleep apnea with obesity, or off-label clinician judgment.

3

Compare access and cost only after eligibility: insurance coverage, cash-pay branded options, compounded pricing, and state or pharmacy availability can differ.

4

Review safety factors before switching or starting: thyroid cancer history, MEN2, pancreatitis history, gallbladder disease, kidney risk from dehydration, pregnancy plans, diabetes medicines, and severe GI disease.

5

Avoid no-prescription GLP-1 sellers, research-use vials, salt forms, guaranteed-result ads, and dose-conversion charts that are not reviewed by a licensed prescriber.

Direct answer

Semaglutide and tirzepatide are once-weekly prescription incretin medicines used in weight-management care, but they are not the same drug. Semaglutide targets GLP-1 receptors; tirzepatide targets GIP and GLP-1 receptors. Tirzepatide often shows greater average weight loss, while the safer choice depends on indication, coverage, side effects, contraindications, and clinician judgment.

Mechanism

What is the main difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. That dual-incretin activity is one reason tirzepatide has shown larger average weight-loss effects in obesity studies and head-to-head analyses. Mechanism alone does not decide the right medication; the clinical decision also depends on diagnosis, insurance, prior response, side effects, and contraindications.

  • Semaglutide brand options include Wegovy for chronic weight management and Ozempic for type 2 diabetes indications.
  • Tirzepatide brand options include Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity, and Mounjaro for type 2 diabetes.
  • Compounded versions require individualized prescription review and are not FDA-approved finished drug products.

Outcomes and expectations

Which usually produces more weight loss?

On average, tirzepatide studies show larger weight reductions than semaglutide studies, and a 2024 JAMA Internal Medicine analysis found greater weight loss among tirzepatide users than semaglutide users in real-world data. That does not mean tirzepatide is automatically better for every patient. Tolerability, coverage, diabetes status, cardiovascular history, sleep-apnea goals, pregnancy plans, and medication interactions can change the recommendation.

  • Semaglutide may be preferred when Wegovy coverage, cardiovascular-risk labeling, prior tolerance, or GLP-1-only familiarity matters.
  • Tirzepatide may be discussed when greater average weight-loss potential, Zepbound coverage, or the obesity-related sleep-apnea indication matters.
  • Slow titration, nutrition, protein intake, resistance training, follow-up, and side-effect management still shape results for either option.

Online access

How should patients compare online clinics?

A useful online comparison asks whether the clinic is making a prescription decision or simply selling a vial. Legitimate GLP-1 care should identify the exact medication, explain branded versus compounded status, review contraindications, use a licensed pharmacy, provide storage and follow-up instructions, and avoid guaranteed weight-loss claims. A cheaper checkout page is not safer if it skips clinician accountability.

  • Ask whether the quote includes intake, clinician review, medication, supplies, shipping, refill support, and side-effect guidance.
  • Ask how the prescriber handles nausea, vomiting, dehydration, constipation, gallbladder symptoms, pancreatitis warning signs, pregnancy plans, and diabetes medication adjustments.
  • Ask whether switching between semaglutide and tirzepatide requires a new medical review rather than a generic dose chart.

Patient safety checklist

Questions to ask before choosing semaglutide or tirzepatide online

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

What exact product is being recommended, and is it branded FDA-approved medication or a prescription compounded preparation?

✓

Is my goal chronic weight management, type 2 diabetes care, cardiovascular-risk reduction, obesity-related sleep apnea, or another clinician-reviewed indication?

✓

Do I have a personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, gallbladder disease, severe GI disease, kidney disease, pregnancy plans, or breastfeeding questions?

✓

Am I using insulin, sulfonylureas, oral contraceptives, blood-pressure medicines, psychiatric medicines, or supplements that should be reviewed before starting?

✓

What side effects should trigger a message, dose pause, urgent care, or a switch rather than self-adjusting treatment?

✓

How are cost, insurance coverage, branded-vs-compounded access, pharmacy source, storage, shipping, and refill timing handled?

✓

If I am switching from one incretin medicine to another, who decides timing, starting dose, and monitoring?

✓

Does the seller avoid salt-form, research-use, no-prescription, and guaranteed-result marketing claims?

FAQs

Short answers for patients

Is tirzepatide stronger than semaglutide?

Tirzepatide has shown greater average weight loss than semaglutide in several studies and real-world comparisons, but “stronger” is not the same as “right for everyone.” The better choice depends on indication, tolerability, contraindications, insurance, cost, and prescriber judgment.

Are semaglutide and tirzepatide both GLP-1 medications?

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is often grouped with GLP-1 care, but technically it is a dual GIP and GLP-1 receptor agonist. Patients should compare the exact drug and label, not only the category name.

Can I switch from semaglutide to tirzepatide online?

Possibly, but switching should be reviewed by a licensed prescriber. Prior dose, side effects, time since last dose, diabetes medicines, pregnancy plans, kidney or gallbladder symptoms, and insurance or pharmacy access can affect the safest transition plan.

Is compounded semaglutide or tirzepatide FDA-approved?

No. Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved brand-name products for specific labeled uses. Compounded semaglutide or tirzepatide may be prescribed for an individual patient when clinically appropriate, but compounded preparations are not FDA-approved finished drug products.

Which costs less: semaglutide or tirzepatide?

Cost depends on insurance coverage, branded versus compounded access, dose, pharmacy model, plan length, and what the clinic includes. Peptide12 lists compounded semaglutide from $199/month and compounded tirzepatide from $329/month, while branded pricing depends heavily on insurance or manufacturer cash-pay programs.

Which has fewer side effects?

Both can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, reflux, abdominal discomfort, reduced appetite, and dehydration risk. Individual tolerance varies. A clinician should review warning signs such as severe abdominal pain, persistent vomiting, allergic symptoms, gallbladder symptoms, or pregnancy.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Wegovy (semaglutide) prescribing informationDailyMed: Zepbound (tirzepatide) prescribing informationJAMA Internal Medicine: Semaglutide vs tirzepatide for weight loss in adults with overweight or obesityNEJM: Once-weekly semaglutide in adults with overweight or obesityNEJM: Tirzepatide once weekly for the treatment of obesityFDA: FDA's concerns with unapproved GLP-1 drugs used for weight lossPeptide12: Compounded semaglutide injectionPeptide12: Compounded tirzepatide injectionPeptide12: WegovyPeptide12: ZepboundPeptide12: GLP-1 medications vs peptide therapyPeptide12: GLP-1 side effects and nauseaPeptide12: Medication interaction reviewPeptide12: How online peptide therapy works